ArticleObstetrics and gynecology international2013
Contemporary clinical management of endometrial cancer.
Article in Obstetrics and gynecology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Endometrial cancer in women with abnormal uterine bleeding: Data mining classification methods.Caspian journal of internal medicine · 2023Article
- Subtotal hysterectomy reviewed: a stable or aperture for stump cervical malignancy. A referral hospital experience.Przeglad menopauzalny = Menopause review · 2022Article
- The association of tumor diameter with lymph node metastasis and recurrence in patients with endometrial cancer: a systematic review and meta-analysis.Translational cancer research · 2022Article
- Diagnostic value and agreement of transrectal in comparison with transvaginal sonography among women with abnormal uterine bleeding.Journal of ultrasound · 2022Article
- Low-Pressure Laparoscopy Using the AirSeal System versus Standard Insufflation in Early-Stage Endometrial Cancer: A Multicenter, Retrospective Study (ARIEL Study).Healthcare (Basel, Switzerland) · 2022Article
- The multistep process of vaginal cancer arising from deep infiltrating endometriosis: a case report.BMC women's health · 2021Article
- SOX17, β-catenin and CyclinD1 expression in the endometrioid adenocarcinoma and influence of 5-AZA on expression.Cancer gene therapy · 2020Article
- The Prognostic Value of Retroperitoneal Lymphadenectomy in Apparent Stage IA Endometrial Endometrioid Cancer.Frontiers in oncology · 2020Article
- Effect of microRNA-29b on proliferation, migration, and invasion of endometrial cancer cells.The Journal of international medical research · 2019Article
- Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions.Hormones & cancer · 2019Review
- Women's preferences for cancer risk management strategies in Lynch syndrome.Gynecologic oncology · 2019Article
- MicroRNA-423 promotes proliferation, migration and invasion and induces chemoresistance of endometrial cancer cells.Experimental and therapeutic medicine · 2018Article
- The clinical significance of occult gynecologic primary tumours in metastatic cancer.Current oncology (Toronto, Ont.) · 2017Article
- Article
- Overexpression of microRNA-205 predicts lymph node metastasis and indicates an unfavorable prognosis in endometrial cancer.Oncology letters · 2016Article
- Androgen receptor as potential therapeutic target in metastatic endometrial cancer.Oncotarget · 2016Article
- Elevation of ω-3 Polyunsaturated Fatty Acids Attenuates PTEN-deficiency Induced Endometrial Cancer Development through Regulation of COX-2 and PGE2 Production.Scientific reports · 2015Article
- Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival.British journal of cancer · 2015Article
- Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.BMC cancer · 2014Article
- ZEB1 expression in endometrial biopsy predicts lymph node metastases in patient with endometrial cancer.Disease markers · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the contemporary management of endometrial cancer is straightforward in many ways, novel data has emerged over the past decade that has altered the clinical standards of care while generating new controversies that will require further investigation. Fortunately most cases are diagnosed at early stages, but high-risk histologies and poorly differentiated tumors have high metastatic potential with a significantly worse prognosis. Initial management typically requires surgery, but the role and extent of lymphadenectomy are debated especially with well-differentiated tumors. With the changes in surgical staging, prognosis correlates more closely with stage, and the importance of cytology has been questioned and is under evaluation. The roles of radiation in intermediate-risk patients and chemotherapy in high-risk patients are emerging. The therapeutic index of brachytherapy needs to be considered, and the best sequencing of combined modalities needs to balance efficacy and toxicities. Additionally novel targeted therapies show promise, and further studies are needed to determine the appropriate use of these new agents. Management of endometrial cancer will continue to evolve as clinical trials continue to answer unsolved clinical questions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.